NVO241213P137000
- 0.00
- 0.000.00%
Novo-Nordisk A/S Newsroom
Positive data from the FLOW renal outcomes trial has led to the updated labeling of semaglutide by Novo-Nordisk A/S being supported by the EMA.
In the FLOW trial, Ozempic significantly reduced the composite risk of progression of renal disease, cardiovascular events, and renal-related mortality by 24% compared to placebo.
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
NVO Gets Positive CHMP Opinion in EU for Ozempic Expanded Use in CKD
Eli Lilly and Co (LLY.US) Mounjaro has replaced Novo-Nordisk A/S (NVO.US) Wegovy as the new favorite weight loss drug in the United Kingdom.
The number of private individuals in the United Kingdom purchasing weight loss drugs is continuously increasing, with Eli Lilly and Co's Mounjaro gradually surpassing Novo-Nordisk A/S's Wegovy, becoming a new favorite among consumers.
Here's Why Novo Nordisk A/S (NVO) Fell in Q3
Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound
Novo Nordisk's Ozempic Gets EU Regulator Endorsement to Reduce Kidney Risks
European Medicines Agency's Committee For Medicinal Products For Human Use Adopted Positive Opinion For Update Of Novo Nordisk's Ozempic
Express News | Novo-Nordisk A/S: After the clinical trial results of the kidney therapy were released, the regulatory authorities in Europe gave a positive label evaluation to Ozempic.
Has Eli Lilly and Co's tirzepatide "defeated" Novo-Nordisk A/S's semaglutide? The competition for weight loss drugs is moving towards "precision breakthroughs."
Industry experts point out that the competition for weight loss drugs is no longer just about rapid weight loss, but requires a "targeted breakthrough" in safety and sustainability aspects, such as reducing weight regain, minimizing muscle loss, increasing medication convenience, and reducing side effects.
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $155
Xi'an Global Printing (002799.SZ): Has maintained a good cooperative relationship with Eli Lilly and Co and Novo-Nordisk A/S.
Gelonghui reported on December 12 that Xi'an Global Printing (002799.SZ) stated on the investor interaction platform that the company has maintained a good cooperative relationship with Eli Lilly and Co, Novo-Nordisk A/S, and other enterprises. In the future, the company will continue to strengthen market development efforts and expand its customer base.
10 Health Care Stocks Whale Activity In Today's Session
Eli Lilly and Co (LLY.US) seeks to expand the indications for its weight loss medication and will conduct trials to treat addictive behaviors.
Eli Lilly and Co will test a weight loss drug for treating addiction in 2025.
BofA Restarts Coverage of 11 Large-cap Biopharmas
Novo Nordisk's Wegovy Sales Drop Is Temporary; Forecasts Still on Track -- Market Talk
Jim Cramer Is 'Not A Fan' Of Novavax, Says This Tech Stock Is 'Expensive'
Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate EKZ-102 Toward Clinical Development
Novo Nordisk Says Investment Aimed At Expanding Enzymes Output Used For The Production Of Insulin, GLP-1 Medicines
Novo Nordisk To Invest Additional 500M Reais To Expand Factory In Brazil